Transglutaminase 2 (TG2, a.k.a. tissue transglutaminase) belongs to a family of transglutaminase enzymes that stabilize proteins by affecting covalent crosslinking via formation of amide bonds. Cell surface TG2 is directly involved as an adhesive receptor in cell-extracellular matrix (ECM) interactions. Here, we show that TG2 activity is elevated in glioblastomas compared with non-neoplastic brain. Immunofluorescent studies showed increased staining of fibronectin colocalized with TG2 in the ECM in glioblastomas. In addition, small clusters of invading human glioblastoma cells present in non-neoplastic brain parenchyma secrete high levels of TG2 and fibronectin that distinguish them from normal brain stroma. Downregulation of TG2 in U87MG glioblastoma cells with RNAi demonstrated decreased assembly of fibronectin in the ECM. Treatment with KCC009 blocked the remodeling of fibronectin in the ECM in glioblastomas in both in vitro and in vivo studies. KCC009 treatment in mice harboring orthotopic glioblastomas (DBT-FG) sensitized the tumors to N,N 0 -bis(2-chloroethyl)-N-nitrosourea chemotherapy, as measured by reduced bioluminescence, increased apoptosis and prolonged survival. The ability of KCC009 to interfere with the permissive remodeling of fibronectin in the ECM in glioblastomas suggests a novel target to enhance sensitivity to chemotherapy directed not only at the tumor mass, but also invading glioblastoma cells.
Introduction
Glioblastomas are among the most difficult malignant neoplasms to treat with median survival after diagnosis of about 12 months (Castro et al., 2003) . One reason for failure to achieve long-term survival in patients with glioblastoma is attributed to high resistance to apoptosis after treatment with radiation or chemotherapy. Glioblastomas have developed alterations in apoptotic regulatory proteins that contribute to their resistance to cell death. Recent studies have demonstrated that modulation of Bcl-2 family proteins may induce apoptosis in glioblastomas. Downregulation of the antiapoptotic proteins Bcl-2 and Bcl-xL with antisense oligonucleotides resulted in a caspase-dependent cell death in glioblastoma cells in vitro (Jiang et al., 2003) . Treatment of glioblastoma cells with lovastatin was associated with upregulation of the proapoptotic BH3-only protein, Bim and enhanced cell death (Jiang et al., 2004) . Thus, glioblastomas are capable of undergoing cell death after modulation of expression of antiapoptotic and proapoptotic proteins. Elucidation of mechanisms that alter sensitivity to chemotherapy may allow for the development of improved clinical strategies directed at new targets.
Transglutaminase 2 (TG2) expression has been associated with resistance to chemotherapy in other tumor types including breast and lung carcinoma cell lines (Mehta, 1994; Han and Park, 1999) . Downregulation of TG2 in PC-14 lung cancer cells increased their sensitivity to doxorubicin. The mechanism of TG2-induced resistance to chemotherapy and apoptosis is not known. In addition to its function to crosslink proteins such as fibronectin and to act as a Ras-like G protein, recent studies have shown that TG2 plays an important antiapoptotic role in cell-matrix signaling by virtue of its high-affinity binding to fibronectin and integrins (Akimov et al., 2000; Zemskov et al., 2006) . We recently proposed that TG2 is important in promoting survival of glioblastoma cells. Treatment of glioblastoma cells in culture with the competitive TG2 inhibitor, monodansylcadarevine (MDC) or with the selective small molecule-irreversible TG2 inhibitor, KCA075, or its analog KCC009 showed an increased incidence of apoptosis . In vivo experiments with a subcutaneous xenograft model with DBT cells demonstrated enhanced sensitivity to chemotherapy in mice co-treated with MDC or with KCC009. Treatment with the combination N,N 0 -bis(2-chloroethyl)-Nnitrosourea (BCNU, carmustine) and either MDC or KCC009 was associated with an increased incidence of apoptosis and an approximately 50% decrease in tumor weight . The mechanism of KCC009-induced enhanced cell death is not known.
We tested the hypothesis that KCC009, a small molecule inhibitor of TG2, interferes with the interaction of TG2 with fibronectin and results in increased sensitivity to chemotherapy. The mechanism of enhanced chemosensitivity in glioblastoma cells after treatment with KCC009 was correlated with altered assembly of fibronectin in the extra-cellular matrix (ECM). TG2 activity and fibronectin levels assessed in frozen tissue samples were elevated in both anaplastic astrocytomas and glioblastoma compared with normal brain. In vitro, KCC009 treatment blocked the assembly of linear strands of fibronectin in the ECM in U87MG cells. Similar observations were made in vivo with a murine orthotopic brain tumor model. Treatment of mice with KCC009 sensitized syngeneic DBT-FG glioblastoma cells to chemotherapy with BCNU. Experiments with intracranial DBT-FG tumors in mice treated with KCC009 and BCNU combination showed decreased tumor growth as measured with bioluminescence imaging, increased apoptosis as determined with TdT-mediated dUTP biotin nick end labeling (TUNEL) staining and prolonged survival. Our findings support a role for KCC009 as a potential novel chemotherapy sensitizer in patients with glioblastomas.
Results
Expression levels of TG2 and fibronectin in human glioblastomas TG2 activity measured with the putrescine incorporation assay in frozen human tissue samples showed an average of 22.0 pmoles/min/mg in glioblastomas (n ¼ 9), 17.8 pmoles/min/mg in anaplastic astrocytomas (n ¼ 6) and 7.5 pmoles/min/mg in non-neoplastic brain (n ¼ 4). The increased TG2 activity measured in glioblastomas was significantly greater than in non-neoplastic brain (Student's t-test Po0.03). TG2 activity from tissue samples from anaplastic astrocytomas and glioblastomas were elevated 2-to 3-fold compared with normal brain tissue (Figure 1a) .
The corresponding tissue specimens were examined with immunofluorescent staining for TG2 and fibronectin. In non-neoplastic brain tissue, there was no significant staining for TG2 and only staining for fibronectin in vascular structures. In contrast, the anaplastic astrocytomas and glioblastoma tissue stained strongly for both fibronectin and TG2. The lower panel in Figure 1 shows a glioblastoma stained with fibronectin (B); TG2 (C) and areas of colocalization of TG2 and fibronectin depicted with yellow staining (D). These findings demonstrate increased levels and activity of TG2 in association with a marked increase in the assembly of dense linear strands of fibronectin that colocalized with TG2 in the ECM.
Expression of fibronectin and TG2 in infiltrating glioblastoma cells in peri-tumoral brain tissue At the time of surgical resection of a glioblastoma, we examined fresh tissue with immunofluorescent staining for expression of fibronectin and TG2 and correlated the findings with corresponding changes on magnetic resonance (MR) imaging. The MR scans in Figure 2 demonstrate a recurrent glioblastoma involving the right temporal lobe of the brain. The MR images show enhancing 'core' tumor on the T1-weighted scan ( Figure 2a , upper image) and abnormal increased signal in the brain surrounding the tumor depicted in the T2-weighted scan (Figure 2a , lower image). Sites of the biopsies are identified by arrows on the respective MR images. Biopsies sites were identified with assistance of stereotactic navigation to allow for accurate correlation with MR images. Neuropathological review of the respective biopsies shows recurrent glioblastoma (T1-weighted MR image) and nuclear atypia (T2-weighted MR image).
Figures 2b-d shows immunofluorescent staining for nuclei (blue), fibronectin (red), TG2 (green) and the merged images. Figure 2b shows staining from nonneoplastic brain from a control specimen. Figure 2c demonstrates dense fibronectin and TG2 staining from the biopsy from the glioblastoma depicted within the gadolinium-enhancing portion of the MR scan. Figure 2d shows a small cluster of tumor cells that invade the peri-tumoral brain and express high levels of TG2 and fibronectin. These infiltrating tumor cells correlated with the biopsy from the abnormal increased signal on the T2-weighted MR scan.
To confirm the neoplastic nature of the infiltrating peri-tumoral cells that express high levels of fibronectin, we evaluated green fluorescent protein (GFP)-labeled DBT-FG glioblastoma cells with an orthotopic brain tumor model. Immunofluorescent staining for GFP and fibronectin from areas of brain outside the tumor mass showed multiple infiltrating clusters of neoplastic cells that co-express GFP and fibronectin (Figure 3) . These findings show similar expression of fibronectin in the infiltrating clusters of murine glioblastoma cells as that demonstrated in human peri-tumoral glioblastoma cells (Figure 2 ).
KCC009 disrupts fibronectin assembly in the ECM in vitro and in vivo U87MG glioblastoma cells were treated with either vehicle or 1.0 mM KCC009 for 24 h. Immunofluroescent staining showed that KCC009 treatment prevented assembly fibronectin strands along the cell surface in the ECM (Figure 4a, b) . KCC009-treated U87MG cells revealed small clumps of fibronectin in the cytosol with minimal presence in the ECM. TG2 stained diffusely throughout the cytosol (Figure 4c, d ). These findings support the hypothesis that KCC009 inhibits the assembly of fibronectin in the ECM of glioblastoma cells.
Orthotopic DBT tumors in mice were examined after five daily treatments with KCC009 (35 mg/kg). Immunofluorescent staining of tumors from vehicle-treated mice demonstrated dense linear strands of fibronectin in the ECM (Figure 4e, g ). In contrast, tumors from KCC009-treated mice showed diminished strands of fibronectin in the ECM. (Figure 4f , h). Thus, changes in fibronectin assembly at the cell surface in tumors after KCC009 treatment were similar in both the above in vivo and in vitro studies.
To verify that the observed differences were associated with KCC009 inhibition of tumor-associated TG2, mice treated with daily intraperitoneal doses of 50 mg/kg KCC009 or vehicle were killed either 15 min or 24 h after the last dose. Tumor-associated TG2 activity was measured (Table 1) . KCC009 treatment led to significant suppression of TG2 activity after 15 min, whereas enzyme activity recovers fully by 24 h. 
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Downregulation of TG2 with RNAi
The ability of TG2 to effect changes in fibronectin assembly in the ECM was assessed with TG2 RNAi. U87MG cells were grown in culture, infected with lentiviral TG2 RNAi and clones selected. Four viable clones were selected, and lysates were examined with Western blots for TG2. U87MG clones demonstrated decreased levels of TG2 as determined with Western blots (Figure 5a ). Immunofluorescent staining of U87MG clones that express reduced levels of TG2 showed decreased assembly of fibronectin in the ECM similar to U87MG cells after treatment with KCC009 ( Figure 5b ). These data support the hypothesis that TG2 is important in promoting the assembly of remodeled fibronectin in glioblastomas.
Orthotopic mouse brain tumor model The efficacy of KCC009 was evaluated with the intracranial DBT-FG glioblastoma model in syngeneic Balb/C mice. Intracranial DBT-FG tumors are similar to human glioblastomas in their aggressive growth pattern, histopathological characteristics and immunoreactivity for glial fibrillary acidic protein (Kumanishi, 1967; Chicoine et al., 2001) . Mice were stereotactically injected with 10 000 DBT-FG cells in the right frontal lobe of the brain. After 3 weeks, the brains were harvested for histopathological examination (Figure 6a 
KCC009 increases sensitivity of DBT-FG cells to BCNU chemotherapy
The ability of KCC009 to sensitize brain tumors to the alkylating agent, BCNU (carmustine), was examined in vivo with bioluminescence imaging. Balb/C mice were stereotactically injected in the right frontal lobe with 10 000 luciferase/GFP-transduced DBT-FG cells. Seven days later, mice were examined with baseline bioluminescence imaging and divided into four groups with equivalent sized tumors. Groups studied included those treated with vehicle-only, KCC009-only, BCNU-only or a KCC009 and BCNU combination therapy. Mice were examined during their exponential growth phase for size with bioluminescence imaging. Mice were treated with daily intraperitoneal injections of 50 mg/kg KCC009 starting on day 7 after tumor implantation, and/or with 2.5 mg/kg BCNU every third day, after an initial dose of 5.0 mg/kg on day 10 after implantation. Tumor size was assessed with bioluminescence imaging on days 10, 14, 18 and 21 (Figure 7a , b). Therapy had a significant effect on relative bioluminescence (analysis of variance (AN-OVA) Po0.001); neither assay day nor the therapyassay day interaction showed such effect (P ¼ 0.42 and 0.96, respectively). Comparison of the bioluminescence KCC009 induces cell death in glioblastomas L Yuan et al on days 14, 18 and 21 versus bioluminescence on day 10 (start of BCNU treatment) showed a significant decrease in relative bioluminescence only in the group treated with the KCC009 and BCNU combination (ANOVA Po0.001). No significant difference (P>0.34) was observed between the groups treated with vehicle-only or with KCC009 or BCNU monotherapy (Figure 7c ). The effects of KCC009-BCNU combination therapy relative to control were most evident on days 18 and 21 (Pp0.004), but less evident on day 14 (P ¼ 0.026).
Tumors were evaluated for the incidence of apoptosis as determined with TUNEL staining in each of the groups. TUNEL-positive cells were quantified and the relative incidence of apoptotic cells in each group was calculated to be 1.0% in the vehicle-treated animals, 1.5 % in the KCC009-treated animals, 1.4 % in the BCNUtreated animals and 3.2% in animals treated with KCC009 þ BCNU combination. The incidence of apoptosis was significantly increased in the KCC009 þ BCNU combination group compared with each of the other groups including control (Po0.002); KCC009-only (Po0.01) and BCNU-only (Po0.02) (data not shown).
To investigate the effect of KCC009 on survival of tumor-bearing mice, DBT-FG tumors were established in 40 mice by implantation of 10 000 DBT-FG cells per mouse. After 1 week the animals were divided into four treatment groups (vehicle-only, KCC009-only, BCNUonly or KCC009 þ BCNU combination) with equivalent baseline bioluminescence emission. KCC009 50 mg/kg treatment was started on day 7 after tumor implantation and intraperitoneal injections of KCC009 continued daily 5 days per week. BCNU was injected at 5 mg/kg on day 10 and 2.5 mg/kg every 5 days thereafter. Length of survival was determined daily. The group receiving KCC009 and BCNU combination showed significant prolongation of lifespan (Kaplan-Meier curve; Figure 8 ). Log rank analysis showed that, compared with the control group, the combination group had substantially increased survival (median survival 29 days control versus 37 days KCC009 þ BCNU; Po0.0004). Monotherapy with KCC009 or with BCNU showed a These in vivo studies suggest that intraperitoneal administration of KCC009 acts across the blood-tumor barrier in the central nervous system (CNS) to inhibit assembly of fibronectin in the ECM and sensitizes intracranial DBT-FG tumors to BCNU chemotherapy. No drug-related fatality or serious adverse effect was observed in any of the KCC009-treated cohorts, suggesting that KCC009 doses up to 50 mg/kg/day are well tolerated in mice. This finding mirrors our data from other experiments where repeat-daily doses up to 100 mg/kg have been well tolerated in mice and rats (data not shown).
Discussion
Tumors may enhance their survival by permissive remodeling of their ECM. One common mechanism involves de novo synthesis of distinctive neo-isoforms of proteins in the ECM such as fibronectin, collagens, laminin or tenascins (Wernert, 1997; Pupa et al., 2002) . These changes in the ECM promote a permissive environment for tumor growth and proliferation. Our findings support the hypothesis that KCC009 interferes with remodeling of fibronectin in the ECM in glioblastomas. Fibronectin functions as an adhesive glycoprotein that plays a key role in promoting survival signals. Fibronectin binds at the cell surface to ECM receptors such as beta1 integrins. The binding of fibronectin to beta1 integrins enhances resistance to chemotherapy (Damiano et al., 1999; Sethi et al., 1999) . Fibronectin binds to alpha5 beta1 integrin through the well-known Arg-Gly-Asp (RGD) binding motif within the Type III domain. The significance of this interaction between fibronectin and integrin in adhesion-mediated survival has been characterized with synthetic agents that competitively bind to the RGD-binding site and enhance apoptosis (Buckley et al., 1999; Hadden and Henke, 2000) . Our findings of expression of fibronectin in both anaplastic astrocytomas and glioblastomas in frozen tumor specimens suggest a potential mechanism in promoting resistance to chemotherapy.
Glioblastomas secrete distinct proteins in the ECM compared with other CNS cells. Fibronectin is deposited in the ECM of glioblastoma cells in a distinctive pattern compared with normal tissue (Ohnishi et al., 1998) . ED-B fibronectin (extra domain B sequence) is a neo-isoform that is a common component found in a number of malignancies (Nicolo et al., 1990) . ED-B fibronectin is derived from alternative splicing of a single KCC009 induces cell death in glioblastomas L Yuan et al gene that encodes fibronectin. It is found in association with malignant tumors and is absent in the great majority of mature non-neoplastic tissue (Midulla et al., 2000) . Studies of fresh tissue from low-grade and high-grade astrocytomas demonstrate a strong correlation for ED-B isoform of fibronectin with highgrade astrocytomas (Castellani et al., 2002) . Thus, identifying an agent that interferes with the permissive remodeling of fibronectin in the ECM in glioblastomas may increase their sensitivity to chemotherapy.
The mechanism whereby treatment of glioblastoma cells with the TG2 inhibitor, KCC009, enhances cell death is not known. In addition to its role as an adhesive co-receptor with fibronectin, TG2 has been associated with other cellular functions that are influenced by its location and micro-environment. Intracellular TG2 may act as a G protein or, depending on Ca 2 þ concentration, may function as a transamidase protein (Fesus and Piacentini, 2002) . After TG2 translocates to the ECM, it functions in a high Ca 2 þ environment that enhances its ability to act as a crosslinking transamidase and stabilize the ECM from mechanical and proteolytic degradation (Aeschlimann and Thomazy, 2000) . The association of TG2 with fibronectin in the ECM results in the formation of TG2-fibronectin complexes with pro-survival characteristics (Verderio et al., 2003) .
Cell surface TG2 crosslinks fibronectin, which acts to stabilize the ECM and anchor cells at the basement membrane (Martinez et al., 1994) . TG2 binds with high affinity to fibronectin at the N-terminal 42-kDa gelatin binding domain of fibronectin via a novel recognition site within the NH 2 -terminal beta-sandwich domain of TG2 (Akimov and Belkin, 2001 ). Our findings of increased levels and activity of TG2 in glioblastomas support a role in tumorigenesis. One potential mechanism of KCC009-enhanced chemo-sensitivity may involve interference of TG2 interaction with fibronectin and assembly in the ECM. Data from TG2 gene-deleted Bioluminescence in an orthotopic intracranial DBT-FG glioblastoma in mice. Mice were stereotactically injected with 10 000 DBT-FG cells in the right frontal lobe of the brain and divided into four treatment groups: vehicle-only; KCC009-only; BCNU-only and KCC009 þ BCNU combination. Mice were treated daily with KCC009 beginning on day 7 without or with BCNU treatment every third day starting on day 10 after tumor implantation. Mice were imaged on day 7, 10, 14, 18 and 21. Representative serial bioluminescence images from a mouse treated with vehicle-only (a) or with the KCC009 þ BCNU combination (b) The graph in (c) shows log transforms of the ratios of bioluminescence from day 14, 18 and 21 over day 10 (the start of BCNU treatment). There was a significant decrease in the ratio of bioluminescence on days 18 and 21 (ANOVA Pp0.004) only in the group treated with the KCC009 þ BCNU combination.
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In conclusion, glioblastomas express increased TG2 levels and activity correlated with fibronectin assembly in the ECM. Infiltrating glioblastoma cells in peritumoral brain parenchyma express elevated TG2 and fibronectin. Downregulation of TG2 with RNAi resulted in decreased assembly of fibronectin in U87MG cells. Treatment with KCC009 blocked the remodeling of fibronectin in the ECM in glioblastomas in both in vitro and in vivo studies. KCC009 treatment of mice harboring glioblastomas sensitized the tumors to BCNU chemotherapy and prolonged survival. The ability of KCC009 to interfere with the permissive remodeling of fibronectin in the ECM in glioblastomas suggests a unique target to enhance sensitivity to chemotherapy directed not only at the tumor mass, but also invading glioblastoma cells. Our findings therefore support a potential role for KCC009 as a novel agent to enhance treatment of glioblastomas.
Materials and methods
Reagents and cell culture BCNU (carmustine), was purchased from Sigma (St Louis, MO, USA).
0 -isoxalyl)methylamide) was prepared as described earlier . U87MG cells were grown in cell culture as described previously . After cells reached 50% confluence, groups were treated with vehicle (1% dimethyl sulfoxide); 0.5 mM, or KCC009 (1.0 mM); or a combination of KCC009 (1.0 mM) and BCNU (6.25 mg/ml) for the designated time periods. Earlier studies have shown that higher KCC009 concentrations are required to elicit an apoptotic response of glioblastoma cells in tissue culture in comparison to in vivo assays in rodents.
In vitro putrescine incorporation assay In vitro TG2 activity was quantified by measuring 14 Cputrescine incorporation into N,N-dimethyl casein . TG2 activity was assayed after various time points following treatment with KCC009. Reaction rates were calculated using linear regression. The activity was calculated as pmoles of putrescine incorporated per minute per mg of total protein. Samples were analysed in duplicate.
Immunofluorescent staining
The levels of both TG2 and fibronectin were examined in frozen specimens of non-neoplastic brain, anaplastic astrocytomas and glioblastomas. The study was approved by the Washington University Institutional Review Board. The tissue was collected in the operating room and stored at the Siteman Cancer Center Tissue Procurement Core Facility. Six micrometer-thick frozen sections were cut and immunostained with a 1:100 titer of mouse anti-human TG2 antibody (NeoMarker, Fremont, CA, USA), with a 1:500 titer anti-GFP antibody (Chemicon, Temecula, CA, USA), and with a 1:400 titer of rabbit anti-human fibronectin antibody (Sigma, St Louis, MO, USA). Subsequently, slides were incubated sequentially with anti-mouse immunoglobulin (Ig)G conjugated with Cy2, antirabbit IgG conjugated with Cy3 (Chemicon, Temecula, CA, USA), and with Hoechst dye 33342 (Sigma, St Louis, MO, USA). Specimens were stained with the commercially available TUNEL kit, In situ Death Detection Kit TMR Red (Pharmingen, BD Biosciences, San Diego, CA, USA) in accordance with the manufacturer's instructions and assessed for incidence of apoptosis as described previously . . Log rank analysis showed the combination group had an increased survival compared with the vehicle-only group with a median survival 37 days in the combination (KCC009 þ BCNU) group versus 29 days in the vehicle-only group; (Po0.0004). Monotherapy with KCC009 or with BCNU showed a trend toward increased survival, but neither group reached a significant increase in median survival.
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Downregulation of TG2 with RNAi U87MG cells were grown in culture to approximately 80% confluence. Lentiviral particles expressing human TG2 RNAi were obtained from Sigma (St Louis, MO, USA). The cells were infected with lentiviral particles (5-25 ml) for 24 h. Recovered cells were grown in standard medium for 24 h and clones were selected with puromicin. The degree of downregulation of TG2 in the U87 clones was determined with Western blots for TG2 from cellular lysates.
Generation of DBT-FG clones and bioluminescence imaging DBT cells were transduced with the lentivirus FUGW-FL which constitutively expresses both firefly luciferase and GFP (Smith et al., 2004) . Cells were infected for 4 h and changed to Dulbecco's modified Eagle's Medium media with 10% heatinactivated fetal bovine serum (DFBS) for 48 h. Transduced cells were screened by bioluminescence imaging and fluorescence microscopy. Selected cells (DBT-FG) were plated individually in a 96-well plate and expanded to produce stable colonies.
For bioluminescence imaging of living animals, Balb/C mice (8 weeks old, female) (Charles River, Wilmington, MA, USA) were injected intraperitoneally with 150 mg/g D-luciferin (Biosynth, Naperville, IL, USA) in phosphate-buffered saline, anesthetized with 2.5% isoflurane and imaged with a chargecoupled device camera-based bioluminescence imaging system (IVIS 50; Xenogen Corp., Alameda, CA, USA; exposure time 1-60 s, binning 8, field of view 12, f/stop 1, open filter). Signal was displayed as photons/s/cm 2 /sr (Gross and Piwnica-Worms, 2005) . Regions of interest (ROI) were defined manually at 95% of the maximum pixel output using Living Image and IgorPro Software (Version 2.50). Data were analysed and plotted as a log ratio of photon flux per given day over photon flux at the start of treatment. Data were analysed by two-way ANOVA using SigmaStat 3.11 (Point Richmond, CA, USA).
Intracranial, orthotopic DBT-FG glioblastoma mouse model and survival study Balb/C mice (20 g), were anesthetized and injected with DBT-FG cells stereotactically in the right frontal lobe of the brain. After 1 week, baseline bioluminescence imaging was performed and animals divided into experimental groups with equivalent tumor burdens. Animals were treated as described in experimental protocols with KCC009 alone or with BCNU. Length of survival for each animal was assessed from the time of implantation of the DBT-FG tumors. In vivo research was performed in accordance with the Washington University Animal Studies Committee guidelines. The data were plotted as Kaplan-Meier curves, and the groups compared with standard log rank tests with Prism 4.0 (GraphPad, San Diego, CA, USA).
